Vertex Pharmaceuticals (VRTX) is making significant strides in the
biotech market. Among the remarkable developments, Vertex has been
celebrated for its groundbreaking CF (
cystic fibrosis) research, secured an EU nod to
expand label for its revolutionary CF treatment, and its diabetes portfolio advances despite a slight decline in share price.
Jim Cramer, the American television personality, former hedge fund manager, and best-selling author, lauds Vertex for its terrific work and sees a revolutionary pain drug on the horizon. He believes the company's potential is enormous. The company also celebrated after receiving an EU victory as their drug
Kaftrio gets approved for an additional 4,000 CF Patients, including children. Vertex looks forward to releasing the first quarter of 2025 financial results on May 5th. With
increased demand for its CF franchise buoying the company's stock, Vertex is seen by investors and billionaires as a sound long-term investment. However, the company did experience some trials with two of its prime drugs, causing its stock to see-saw. Nevertheless, the developments it has made and its potential keeps the company firmly in the spotlight.
Vertex Pharmaceuticals VRTX News Analytics from Wed, 25 Sep 2024 07:00:00 GMT to Sat, 12 Apr 2025 16:00:11 GMT -
Rating 6
- Innovation 8
- Information 7
- Rumor -3
